Cardiomyopathy Trial, Recruiting NCT05760924 Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences Condition: Cardiomyopathy
Back to Cardiomyopathy

Cardiomyopathy Trial, Recruiting

NCT05760924
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are willing to follow the study rules and have signed a consent form agreeing to take part
  • You are between 18 and 80 years old (male or female)
  • You have been diagnosed with a type of heart failure caused by blocked arteries (ischemic) or another cause (non-ischemic)
  • You have had heart failure symptoms for at least 3 months before joining the study
  • Your heart failure symptoms are at least moderate in severity (you experience symptoms during normal activity or even at rest)
  • You already have a CRT-D device (a special pacemaker for heart failure) that has not improved your heart function enough — meaning your heart pumping ability has not improved sufficiently and/or your heart has not reduced in size enough after at least 1 year with the device, and the device battery or one of its leads needs replacing
  • You are already receiving the best available standard medical treatment for your heart failure

Who may not be able to join:

  • You have had heart bypass surgery, a balloon procedure, or a stent placed in a heart artery within the last 3 months
  • You have had a heart attack within the last 3 months
  • You are currently experiencing an acute coronary syndrome (a sudden, serious heart condition such as an unstable angina or heart attack)
  • You are scheduled to have heart bypass surgery, a balloon procedure, or a stent in the near future
  • You are on a waiting list for a heart transplant
  • You already have a mechanical heart assist device implanted
  • You currently have acute inflammation of the heart muscle (acute myocarditis)
  • You have a disease where abnormal substances have built up in the heart muscle (confirm with trial site)
  • You have a condition where the heart muscle is abnormally thick (hypertrophic cardiomyopathy)
  • You have severe problems with your mitral, tricuspid, or aortic heart valves (either severely narrowed or severely leaking)
  • You are currently pregnant, breastfeeding, or not using reliable contraception if you are of childbearing age
  • You have a physical or mental condition that would prevent you from taking part in the study
  • You are unwilling or unable to follow the study procedures
  • You have rheumatic heart disease (heart damage caused by rheumatic fever)
  • You have a mechanical (artificial) tricuspid heart valve
  • You have another serious medical condition that could affect the study results (confirm with trial site)
  • You are currently taking part in another study testing an experimental drug or device
  • You would not be available for follow-up appointments during the study
  • You have severe chronic kidney disease (your kidneys are functioning at a significantly reduced level — confirm with trial site)
  • Your life expectancy is 12 months or less
  • You are already taking part in another remote heart monitoring programme

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Tariel A Atabekov, Ph.D., Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences

Phone: +79528002625

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Tomsk National Research Medical Center of the Russian Academy of Sciences
Registry
ClinicalTrials.gov
Start date
1 November 2024
Est. completion
1 June 2028

Where this trial is recruiting

🇷🇺 Russia

Primary endpoints

All-cause mortality or worsening of heart failure requiring unplanned hospitalization (%)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov